Biotechnology

As Everest Medicines preps its H1 2026 results, investors are watching for more than just profit, focusing on its pivot to a global innovation engine.

Attovia Therapeutics’ successful IPO injects massive capital into its ambitious pipeline, but can its novel multi-specific antibody platform outmaneuver giants?

Editas Medicine’s new board member signals a sharp focus on cardiovascular disease, a strategic pivot that could reshape the competitive gene editing race.

With a fortified balance sheet and a strategic pivot, OnKure Therapeutics is betting that precision and selectivity will conquer a competitive drug market.

Amid a biotech funding revival, Twist's upsized $300M deal signals a bold move to expand its synthetic biology platform, fueling a high-stakes investor debate.

A new partnership unites AI data-crunching with lab-grown human brain organoids, charting a bold roadmap to deconstruct Parkinson's into treatable subtypes.

Immix Biopharma heads to Morgan Stanley's key conference. Can its promising CAR-T therapy for AL Amyloidosis convince investors to fund the final mile?

A strategic investment in Carolina Components Group signals a larger PE trend: fortifying the single-use technology supply chain to de-risk drug manufacturing.

In a strategic play, Archeus Technologies overhauls its advisory board, positioning itself to accelerate its cancer therapy pipeline in the booming RPT market.

Entropy Neurodynamics launches a world-first 'basket study' for its IV psilocin, a high-stakes bet that could redefine mental health treatment pipelines.

A new oral tablet from Entera Bio could replace painful daily injections for millions with severe osteoporosis, a move validated by a top scientific conference.

An AI-driven biodefense firm is using anti-racketeering laws to fight alleged market fraud. Is this a landmark battle for market integrity?

Healis Therapeutics gets FDA nod for Tyemvers, a botulinum toxin therapy for depression. Can a drug that paralyzes frown muscles disrupt mental healthcare?

After a corporate overhaul and a massive cash infusion, Faeth Therapeutics is pushing its multi-pronged cancer drug PIKTOR toward pivotal clinical data.

As Tecan prepares to unveil its H1 2026 results, the numbers will offer more than a corporate health check—they are a key signal for the entire lab automation industry's recovery.

Hidehiko Otake's promotion isn't just a corporate shuffle. It’s a bet that Corundum can turn our deepest biological data into the future of medicine.

By partnering with major CROs, Revolune is tackling a key bottleneck in advanced tissue analysis. This new ecosystem could change how labs of all sizes innovate.

Oblenio Bio's LBL-051 enters human trials, offering hope for a true "immune reset" and drug-free remission for severe autoimmune disease patients.

Vantage Biosciences has completed enrollment for its oral drug, oruvestat, a potential game-changer for early diabetic retinopathy. This could replace invasive injections.

A strategic delegation of 15 AI startups signals a new era. Taipei is not just selling tech; it's building a deep innovation ecosystem with Japan.